{
    "clinical_study": {
        "@rank": "127974", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Combining more than one drug may kill more tumor cells.\n\n      PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy\n      consisting of cyclophosphamide, vincristine, and prednisolone, with either mitoxantrone or\n      doxorubicin in treating patients with intermediate- or high-grade non-Hodgkin's lymphoma."
        }, 
        "brief_title": "Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma", 
        "completion_date": {
            "#text": "January 2001", 
            "@type": "Actual"
        }, 
        "condition": "Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, Large-Cell, Immunoblastic"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Assess the treatment-related neurologic and hematologic toxicities of\n      patients aged 65 years and over with intermediate- or high-grade non-Hodgkin's lymphoma\n      randomized to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) vs. MCOP\n      (mitoxantrone, cyclophosphamide, vincristine, prednisolone). II. Compare the survival rate\n      in these patients.\n\n      OUTLINE: Randomized study. The following acronyms are used: CHOP CTX/DOX/VCR/PRDL CTX\n      Cyclophosphamide, NSC-26271 DHAD Mitoxantrone, NSC-301739 DOX Doxorubicin, NSC-123127 MCOP\n      DHAD/CTX/VCR/PRDL PRDL Prednisolone, NSC-9900 VCR Vincristine, NSC-67574 Arm I: 4-Drug\n      Combination Chemotherapy. CHOP. Arm II: 4-Drug Combination Chemotherapy. MCOP.\n\n      PROJECTED ACCRUAL: A total of 200 patients will be entered over approximately 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically confirmed intermediate- or high-grade non-\n        Hodgkin's lymphoma of the following types: Diffuse centroblastic Diffuse immunoblastic B-\n        and T-cell lymphoblastic Peripheral T-cell (mixed or large cell) and Ki-1 No Stage IA\n        (nonbulky) disease suitable for radiotherapy alone\n\n        PATIENT CHARACTERISTICS: Age: 65 and over Performance status: Not specified Hematopoietic:\n        Not specified Hepatic: Not specified Renal: Not specified Cardiovascular: No severe\n        ischemic heart disease No cardiomyopathy that would restrict doxorubicin use Other: No\n        other serious medical conditions that would affect treatment outcome No prior malignancy\n        except: Nonmelanomatous skin cancer Adequately treated in situ cervical cancer\n        Sufficiently fit to receive treatment\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery:\n        Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002576", 
            "org_study_id": "CRC-TU-NH3003", 
            "secondary_id": [
                "CDR0000063660", 
                "EU-93028", 
                "ISRCTN39268693"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "doxorubicin hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "mitoxantrone hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "prednisolone", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "vincristine sulfate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Doxorubicin", 
                "Prednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Mitoxantrone", 
                "Vincristine", 
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Methylprednisolone", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate"
            ]
        }, 
        "keyword": [
            "stage I adult diffuse mixed cell lymphoma", 
            "stage I adult diffuse large cell lymphoma", 
            "stage I adult immunoblastic large cell lymphoma", 
            "stage I adult lymphoblastic lymphoma", 
            "stage I adult Burkitt lymphoma", 
            "stage II adult diffuse mixed cell lymphoma", 
            "stage II adult diffuse large cell lymphoma", 
            "stage II adult immunoblastic large cell lymphoma", 
            "stage II adult lymphoblastic lymphoma", 
            "stage II adult Burkitt lymphoma", 
            "stage III adult diffuse mixed cell lymphoma", 
            "stage III adult diffuse large cell lymphoma", 
            "stage III adult immunoblastic large cell lymphoma", 
            "stage III adult lymphoblastic lymphoma", 
            "stage III adult Burkitt lymphoma", 
            "stage IV adult diffuse mixed cell lymphoma", 
            "stage IV adult diffuse large cell lymphoma", 
            "stage IV adult immunoblastic large cell lymphoma", 
            "stage IV adult lymphoblastic lymphoma", 
            "stage IV adult Burkitt lymphoma", 
            "contiguous stage II adult diffuse mixed cell lymphoma", 
            "contiguous stage II adult immunoblastic large cell lymphoma", 
            "contiguous stage II adult diffuse large cell lymphoma", 
            "contiguous stage II adult Burkitt lymphoma", 
            "contiguous stage II adult lymphoblastic lymphoma", 
            "noncontiguous stage II adult diffuse mixed cell lymphoma", 
            "noncontiguous stage II adult immunoblastic large cell lymphoma", 
            "noncontiguous stage II adult diffuse large cell lymphoma", 
            "noncontiguous stage II adult Burkitt lymphoma", 
            "noncontiguous stage II adult lymphoblastic lymphoma"
        ], 
        "lastchanged_date": "August 6, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/CRC-TU-NH3003"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Nottingham", 
                    "country": "United Kingdom", 
                    "state": "England", 
                    "zip": "NG5 1PB"
                }, 
                "name": "Nottingham City Hospital NHS Trust"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "official_title": "A RANDOMIZED PROSPECTIVE TRIAL OF CHOP VERSUS MCOP IN ELDERLY PATIENTS WITH INTERMEDIATE AND HIGH GRADE NON-HODGKIN'S LYMPHOMA (AGED 65 YEARS AND OVER)", 
        "overall_official": {
            "affiliation": "Nottingham City Hospital", 
            "last_name": "Eric Michael Bessell, MD, PhD, FRCP, FRCR", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002576"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cancer Research Campaign Clinical Trials Centre", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 1992", 
        "study_design": "Allocation: Randomized, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2007"
    }, 
    "geocoordinates": {
        "Nottingham City Hospital NHS Trust": "52.955 -1.158"
    }
}